scholarly journals Studi Pendahuluan Profil Penggunaan Obat dan Kepatuhan terhadap Pengobatan pada Pasien Lupus di Komunitas

2015 ◽  
Vol 2 (1) ◽  
pp. 78
Author(s):  
Sylvi Irawati ◽  
Adji Prayitno ◽  
Angel Angel ◽  
Rosati Herma Safitri
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Pill Count ◽  
Systemic Lupus ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

Penelitian ini bertujuan untuk memberikan gambaran mengenai penggunaan obat dan kepatuhan pasien systemic lupus erythematosus (SLE) terhadap pengobatannya. Desain penelitian ini bersifat observational dan prospektif. Pasien SLE yang berpartisipasi dalam penelitian adalah pasien yang berusia ≥18 tahun, sedang menggunakan obat SLE, dan bersedia berpartisipasi. Pengumpulan data dilakukan selama bulan September sampai dengan November 2012. Metode pengumpulan data yang digunakan adalah observasi dan wawancara. Metode pill count digunakan untuk mengukur kepatuhan pasien. Terdapat 15 pasien yang bersedia berpartisipasi dalam penelitian. Seluruh pasien tersebut berjenis kelamin perempuan dengan median usia 30 tahun. Sebanyak 3 pasien menerima 1 macam obat, sementara sisanya menggunakan kombinasi obat. Semua pasien menggunakan corticosteroids. Sebanyak 12 pasien menggunakan kombinasi corticosteroids dengan 1 atau 2 obat dari golongan disease-modifying antirheumatic drugs (DMARDs). Lebih dari 50% pasien tidak patuh terhadap pengobatan. Penelitian lebih lanjut dibutuhkan untuk menggali faktor-faktor yang menghambat kepatuhan pasien terhadap pengobatan serta untuk menghasilkan strategi perbaikan bagi masalah ini.

scholarly journals The prevalence of COVID-19 in patients with rheumatoid arthritis, multiple sclerosis, or systemic lupus erythematosus receiving biologic disease-modifying antirheumatic drugs

2021 ◽  
Vol 7 (2) ◽  
pp. e35-e35
Author(s):  
Arman Ahmadzadeh ◽  
Faraneh Farsad ◽  
Mohammad Mehdi Emam ◽  
Alireza Rajaei ◽  
Samaneh Hatami ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Multiple Sclerosis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Lower Risk ◽  
Systemic Lupus ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Biologic Dmards ◽  
Disease Modifying

Introduction: The coronavirus disease (COVID-19) became a global pandemic in 2019. Some studies have shown that the virus can cause a higher mortality in people with weakened immune systems, such as the elderly, those taking immunosuppressive drugs, and those with underlying disorders, than in the general population. Objectives: The aim of this study was to evaluate the prevalence of COVID-19 in patients with rheumatic disorders who received biologic disease-modifying antirheumatic drugs (DMARDs). The effect of precautionary self-isolation in these patients was also determined. Patients and Methods: This descriptive study involved 200 patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS) who were treated with biologic DMARDs. Patients with symptoms of the coronavirus infection were invited to have a COVID-19 test that involved a COVID-19 IgG antibody test or a polymerase chain reaction (PCR) test (i.e., nasal swab). Additionally, patients were asked about their precautionary self-isolation status during this period. Results: The mean age of the patients was 51.29 years ± 13.38 years. The ratio of males to females was 27 to 173. Of the 200 patients included in the study, 156 (78%) had RA, 10 (5%) had SLE, and 34 (17%) had MS. Seventy-five percent of the patients used rituximab. Ten patients (5%) were symptomatic of COVID-19, although only four patients had a definitive diagnosis of the disease. All patients who were symptomatic of COVID-19 took rituximab. Ten percent of patients who did not observe the precautionary self-isolation period were diagnosed with COVID-19. Conclusion: Patients who receive biologic DMARDs have a lower risk of developing COVID-19 and a lower risk of mortality from the disease than the general population.

scholarly journals FRI0526 THE INCIDENCE, PREVALENCE AND MEDICATION USE OF RHEUMATOID ARTHRITIS AMONG KOREAN WOMEN IN CHILDBEARING YEARS: A NATIONWIDE POPULATION-BASED STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 862.2-863
Author(s):  
M. K. Chung ◽  
J. S. Park ◽  
H. S. Lim ◽  
C. H. Lee ◽  
J. Lee
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Medication Use ◽  
Population Based ◽  
Korean Women ◽  
Childbearing Age ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying ◽  
Incidence Prevalence

Background:Rheumatoid arthritis (RA) predominantly affects women and has a significant impact on childbearing. Several population-based studies identifying incidence, prevalence, and medication use of RA have been reported, yet epidemiological studies focusing on women with RA in childbearing years are missing.Objectives:We aimed to identify the incidence, prevalence and medication use of RA among Korean women in childbearing years.Methods:From National Health Insurance Service (NHIS) data (2009-2016), containing inpatient and outpatient claim information for approximately 97% of the Korean population, we identified 9,217,139 women aged between 20-44 years. Incidence and prevalence of RA in the specific sociodemographic group of women in childbearing age were analyzed, and the prevalence of medication prescription were compared between women with RA and controls without rheumatic diseases such as RA, systemic lupus erythematosus, and ankylosing spondylitis. Individuals with RA were defined by the presence of International Classification of Disease, 10th revision code, M05. The medication use was defined as receiving > 90days prescriptions of NSAIDs, corticosteroids (CSs), and conventional synthetic (cs) disease modifying antirheumatic drugs (DMARDs) or > 1day prescription of biologic (b) DMARDs.Results:Total 24,590 women with RA were identified. The average incidence of RA during 2011-2016 among women in childbearing years was 24.1/100,000 person-years (PYs) (95% CI 20.91-27.31) with a yearly increase from 20.99/100,000 PYs in 2011 to 28.38/100,000 PYs in 2016. The average prevalence of RA during 2009-2016 among women in childbearing years was 105.2/100,000 PYs (95% CI 99.0-111.5) with a minimum of 95.7/100,000 PYs in 2009 and a maximum of 110.5/100,000 PYs in 2016. There were increasing trends in both incidence and prevalence of RA according to age among women in childbearing years peaking in the age group of 40-44 years. The prescriptions of NSAIDs, CSs, csDMARDs and bDMARDs were more frequent in women with RA than controls (NSAIDs; 94.21% vs 21.79%, CSs; 83.65% vs 4.28%, csDMARDs; 91.23% vs 0.41%, bDMARDs; 0.11% vs 0%, p<0.001).Conclusion:The incidence and prevalence of RA are high among Korean women in childbearing years, and medication use was significantly more frequent in this specific population than controls. High disease burden is imposed upon women in childbearing years.References:[1] Won S, Cho SK, Kim D, Han M, Lee J, Jang EJ, Sung YK, Bae SC: Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization. Rheumatol Int 2018, 38(4):649-656.[2] Smeele HTW, Dolhain R: Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis. Seminars in arthritis and rheumatism 2019, 49(3s):S32-s35.Table 1.Medication use among women with RA and controls in childbearing age between 20-44 years during 2009-2016Control(n=155,486)RA(n=23,756)n(%)n(%)PNSAIDs33,887(21.79)22,380(94.21)<.0001Steroids6,653(4.28)19,871(83.65)<.0001csDMARDs634(0.41)21,673(91.23)<.0001bDMARDs0(0.00)27(0.11)<.0001RA, rheumatoid arthritis; NSAID, non-steroidal anti-inflammatory drug; cs, conventional synthetic; b, biologic; DMARDs, disease modifying antirheumatic drugsDisclosure of Interests:None declared

Scleritis, keratitis, and orbital cellulitis: isolated ocular manifestation of systemic lupus erythematosus

Lupus ◽  
2018 ◽  
Vol 27 (12) ◽  
pp. 1985-1988
Author(s):  
W V Lin ◽  
M Saumur ◽  
Z Al-Mohtaseb
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Disease ◽  
Orbital Cellulitis ◽  
Systemic Lupus ◽  
Disease Modifying Antirheumatic Drugs ◽  
Systemic Autoimmune Diseases ◽  
Ocular Manifestations ◽  
Inflammatory Conditions ◽  
Microbial Etiology

Systemic autoimmune diseases are associated with ocular inflammatory conditions such as episcleritis, scleritis, keratitis, and uveitis. However, ocular manifestations have been reported to correlate with the extent of systemic disease. We present a patient with scleritis, keratitis, and orbital cellulitis, as the isolated manifestation of systemic lupus erythematosus (SLE). No microbial etiology was identified and antibiotics did not produce clinical improvement. The patient improved significantly with steroids and disease-modifying antirheumatic drugs. Although ocular inflammation has been previously remarked in SLE of systemic severity, in this case there were no other organs with SLE involvement. We briefly discuss the ocular manifestations of SLE, which can involve all segments of the eye, including cornea, sclera, retina, uvea, optic nerve, and orbit.

scholarly journals Objective assessment of the damaging effect of glucocorticoids (toxicity index) in patients with systemic lupus erythematosus

2021 ◽  
Vol 15 (6) ◽  
pp. 111-116
Author(s):  
N. Yu. Nikishina ◽  
E. V. Ermolaeva ◽  
A. A. Mesnyankina ◽  
E. A. Aseeva ◽  
S. K. Soloviev ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Objective Assessment ◽  
Great Success ◽  
Systemic Lupus ◽  
Disease Modifying Antirheumatic Drugs ◽  
Multisystem Disease ◽  
Irreversible Damage ◽  
Toxicity Index ◽  
Selection Of

Systemic lupus erythematosus (SLE) is a multisystem disease characterized by chronic inflammation and damage to vital organs and systems. Despite the great success achieved in the treatment of SLE, glucocorticoids (GC) remain one of the main methods of therapy. The GC toxicity index is an objective method for assessing adverse events associated with their use, and in future studies can be actively used to monitor the safety of various therapy regimens. Wider introduction of this index in the management of patients with SLE will allow to optimize approaches to the selection of GC doses, to consider earlier prescription of biologic disease modifying antirheumatic drugs, before the development of severe irreversible damage. 

scholarly journals Complicated management of patients with systemic lupus erythematosus.

2018 ◽  
Vol 96 (5) ◽  
pp. 463-471
Author(s):  
N. V. Seredavkina ◽  
T. M. Reshetnyak ◽  
E. L. Nasonov
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Lupus Erythematosus ◽  
Adverse Reactions ◽  
Systemic Disease ◽  
Genetic Defects ◽  
Systemic Lupus ◽  
Antirheumatic Drugs ◽  
Autoimmune Inflammation ◽  
Human Intravenous Immunoglobulin

Systemic lupus erythematosus (SLE) - chronic systemic disease, which associates with genetic defects of immunoregulatory processes and leads to uncontrolled production of antibodies to native cells and its elements with autoimmune inflammation development. There is a case report of human intravenous immunoglobulin use in lupus patient with the multiple resistances to antirheumatic drugs and many adverse reactions of the therapy.

Systemic lupus erythematosus

2018 ◽  
pp. 343-374
Author(s):  
Gavin Clunie ◽  
Nick Wilkinson ◽  
Elena Nikiphorou ◽  
Deepak R. Jadon
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Broad Spectrum ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Systemic Lupus ◽  
Detailed Review ◽  
Disease Modifying ◽  
Novel Therapeutic

The multisystem, autoimmune nature of systemic lupus erythematosus (SLE) and its broad spectrum of presenting clinical manifestations are explored in detail in this chapter. Important comorbidities and associations between SLE and the antiphospholipid syndrome and pregnancy are also discussed. The chapter details the various autoantibodies associated with the disease, along with their prevalence and associated clinical features. In addition, it provides a detailed review of the management of SLE, starting from conservative measures through to disease-modifying, immunosuppressive therapy to plasma exchange and stem cell transplantation. Novel therapeutic agents are also summarized, along with a note on prognosis. The chapter includes a section on childhood and neonatal SLE, covering presentation, relevant investigations, and treatment.

Sign in / Sign up

Export Citation Format

Share Document